证券代码：688575 证券简称：亚辉龙 公告编号：2025-039 深圳市亚辉龙生物科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 股东大会有关情况 股份类别 股票代码 股票简称 股权登记日 A股 688575 亚辉龙 2025/5/19 二、 增加临时提案的情况说明 公司已于2025 年 4 月 25 日公告了股东大会召开通知，单独持有38.95%股份 的股东胡鹍辉，在2025 年 5 月 15 日提出临时提案并书面提交股东大会召集人。 股东大会召集人按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》有关规定，现予以公告。 东胡鹍辉先生提交的《关于向深圳市亚辉龙生物科技股份有限公司提请增加 专门委员会委员的议案》至公司计划于 2025 年 5 月 26 日召开的 2024 年年度股 东大会审议。 三、 除了上述增加临时提案外，于2025 年 4 月 25 日公告的原股东大会通知 事项不变。 四、 增加临时提案后股东大会的有关情况。 （一） 现场会议召开的日期、时间和地点 召开 ...

Investment Rating - The report maintains a "Buy" rating for Legend Biotech (LEGN US) with a target price of $65.00, indicating a potential upside of 100.7% from the current price of $32.38 [1][8]. Core Insights - Carvykti is experiencing steady growth, with a 10% quarter-over-quarter increase in 1Q25 sales, driven by new production capacity, new indications, and market expansion. The report suggests that the current market concerns regarding competition and drug pricing reforms are overstated, supporting the "Buy" rating [2][4]. - The revenue forecasts for Legend Biotech have been adjusted downward for 2025, 2026, and 2027, reflecting a 9.5%, 5.4%, and 1.8% decrease respectively. The projected revenues are $960 million, $1.4 billion, and $1.797 billion for those years [3][9]. Financial Projections - The updated financial model predicts the following for Legend Biotech: - 2025E Revenue: $960 million - 2026E Revenue: $1.4 billion - 2027E Revenue: $1.797 billion - 2025E Gross Profit: $596 million with a gross margin of 62.1% [3][9]. - The net loss for 1Q25 was reported at $101 million, but adjusted net loss excluding non-operating items was significantly reduced to $27 million compared to a net loss of $85 million in 1Q24 [4][9]. Market Performance - The stock has shown a year-to-date change of -0.49%, with a 52-week high of $59.88 and a market capitalization of approximately $5.95 billion [2][9]. - The report highlights that the market is currently undervaluing the stock, as it trades at 1.7 times the peak revenue multiple, indicating significant investment value [4][5].

Group 1 - The mayor emphasizes the importance of major projects as a stabilizing force for growth and development, urging all levels of government to prioritize project execution and expand effective investment [2] - The construction of the Nanjing North Station hub is highlighted as a significant project with high social attention, requiring coordinated efforts among various departments to overcome challenges and ensure quality [1] - The focus on the high-end chemical project at Jinling Petrochemical aims to enhance the development of the petrochemical industry towards high-end, intelligent, and green growth [1] Group 2 - The mayor calls for a strong organizational approach to project implementation, focusing on key indicators such as start-up rates and investment rates, to ensure timely problem resolution and effective project execution [2] - There is an emphasis on the need for precise and efficient service to meet project demands, ensuring resource allocation and support for enterprises [2] - The mayor encourages companies to focus on market demands and accelerate the application of innovative results to foster new growth points [1]

Group 1 - The core viewpoint highlights the acceleration of project construction in Heilongjiang as a vital strategy for achieving high-quality economic development, with a significant increase in the number of projects initiated compared to the previous year [1][2] - In the first quarter, the number of projects started or resumed in the province increased by 1,525, representing a growth of 51.8%, which contributed to a 15.2% increase in fixed asset investment, surpassing the national average of 10.7% [1] - The provincial government has established a daily scheduling mechanism for investment projects, ensuring precise management from land approval to construction permits, supported by a special fund of 500 million yuan to enhance the quality and speed of major government investment projects [1][2] Group 2 - Heilongjiang is leveraging industrial projects to drive economic transformation and upgrading, with the establishment of a dedicated task force for major industrial projects and a comprehensive management mechanism integrating various project types [2] - In the first quarter, 477 provincial-level key industrial projects were launched, covering high-end manufacturing, new materials, and green food sectors, indicating a strategic focus on future growth [2] - By the end of April, 740 out of 1,000 provincial-level key industrial projects had resumed work, with a total investment of 23.06 billion yuan, and notable growth in manufacturing and private investment, indicating an increase in investment quality [2][3] Group 3 - The rapid progress of specific projects, such as the Qiqihar plant protein milk project, demonstrates the effectiveness of streamlined approval processes and innovative service methods by local authorities, significantly reducing approval times [3] - The construction of the Daqing biological enzyme project showcases the collaborative efforts of local government and businesses, enhancing the local economy and extending the biological economy industry chain [3] - Overall, Heilongjiang is utilizing project construction as a lever to optimize investment structure and elevate industrial capabilities across various sectors [3]

Market Overview - Major industry ETFs showed mixed performance, with semiconductor ETFs rising over 1% and global technology stock index ETFs increasing nearly 1%, while utility and energy ETFs declined by over 1% [1] Semiconductor Sector - Semiconductor ETF price reached 248.30, with an increase of 2.74 (+1.12%), and a trading volume of 714,800 shares, totaling a market value of 29.35 billion, reflecting a year-to-date increase of 2.53% [2] Technology Sector - Global technology stock index ETF priced at 85.42, up by 0.70 (+0.82%), with a trading volume of 5,259 shares and a market value of 11.96 billion, showing a year-to-date increase of 0.79% [2] - Technology sector ETF at 234.27, increased by 1.65 (+0.71%), with a trading volume of 414,300 shares and a market value of 745.11 billion, reflecting a year-to-date increase of 0.93% [2] Utility and Energy Sectors - Utility ETF priced at 78.58, decreased by 1.07 (-1.34%), with a trading volume of 853,600 shares and a market value of 11.41 billion, showing a year-to-date increase of 4.56% [2] - Energy sector ETF at 85.12, down by 0.65 (-0.76%), with a trading volume of 1,037,900 shares and a market value of 21.32 billion, reflecting a year-to-date increase of 0.14% [2]

Core Viewpoint - The article discusses the common pharmaceutical indices in A-shares and Hong Kong stocks, their classifications, current valuations, and available funds for investment opportunities in the pharmaceutical sector [1]. Group 1: Classification of Indices - The common indices in A-shares and Hong Kong stocks are categorized into four types: broad-based indices, strategy indices, industry indices, and thematic indices [5][6][7][8][9]. - Broad-based indices select stocks based on market capitalization and cover various industries [6]. - Strategy indices are based on broad-based indices but apply specific investment strategies, catering to diverse investor needs [7]. - Industry indices focus on specific sectors, such as pharmaceuticals, and are essential for long-term societal development [8]. - Thematic indices are related to specific themes like technology and renewable energy, covering multiple industries but not as extensively as broad-based indices [9]. Group 2: Pharmaceutical Industry Insights - The pharmaceutical industry is highlighted as a naturally profitable sector due to its essential nature in human life [11][12]. - Demand for pharmaceuticals remains stable regardless of economic downturns or natural disasters [13]. - Over decades, the pharmaceutical industry has consistently performed well, with the CSI Pharmaceutical Index (code 000933) showing a growth of over six times from 1000 points in December 2004 to 7602 points by April 2025 [15][16]. Group 3: Sub-industry Indices - The pharmaceutical sector includes three main sub-industry indices: medical services, biotechnology, and innovative drugs [18]. - The medical industry comprises medical services and devices, with a significant number of funds available for investment [19]. - Biotechnology focuses on gene diagnostics, biopharmaceuticals, blood products, and human biotechnology, showing comparable long-term returns to the medical sector [20]. - Innovative drugs primarily involve pharmaceutical companies, with many firms operating in both biotechnology and innovative drugs [22]. Group 4: A-shares and Hong Kong Stocks Pharmaceutical Indices - A summary of common pharmaceutical indices in A-shares and Hong Kong stocks is provided, including representative indices and their respective sub-indices [26]. - The CSI Pharmaceutical Index represents large and mid-cap pharmaceutical stocks, while the Full Pharmaceutical Index covers a broader range of companies [28][30]. - The Hong Kong Hang Seng Medical Care Index is the primary pharmaceutical index in Hong Kong, with similar definitions to the A-share pharmaceutical indices [33][34]. Group 5: Historical Performance and Valuation - The A-share pharmaceutical industry has experienced several bull and bear markets, with annualized returns of 10.5% for the CSI Pharmaceutical Index and 10.91% for the Full Pharmaceutical Index [42]. - The pharmaceutical indices are currently at relatively low valuation levels, with price-to-earnings ratios generally higher than price-to-book ratios due to fluctuations in industry profitability [47][48]. - The historical performance of the CSI Medical Index shows an annualized return of 9.47%, indicating potential for higher long-term returns as it rebounds from current lows [60]. Group 6: Index Funds - Various index funds related to pharmaceutical indices are available in both A-shares and Hong Kong stocks, with similar fee structures [51]. - The scale of these funds is generally small, reflecting their recent establishment [52].

Investment Rating - The report maintains a "Buy" rating for the Hong Kong stock and a "Hold" rating for the A-share, with target prices set at HKD 11.7 and CNY 19.6 respectively [5][12]. Core Insights - The company's Q1 2025 performance slightly exceeded expectations, with total revenue reaching RMB 381 million, representing a year-on-year increase of 129.9% and a quarter-on-quarter increase of 22.3% [2][3]. - The revenue from the drug Oubatinib was RMB 311 million, showing a year-on-year growth of 89.2% and a quarter-on-quarter growth of 1.2% [2][3]. - The management has raised the full-year revenue growth guidance for Oubatinib from 30% to 35% year-on-year, driven by strong sales in exclusive indications and market share gains [3][12]. Financial Performance Summary - Q1 2025 net profit attributable to shareholders was RMB 17.97 million, which is an improvement compared to previous losses, primarily due to better-than-expected revenue and lower sales and administrative expenses [2][3]. - The gross margin for product sales improved to 88.4%, up from 85.3% in Q1 2024 and 87% in Q4 2024 [2][3]. - The company expects significant contributions from the MZL indication to Oubatinib's overall revenue, increasing from 30% in 2024 to 50% in 2025 [3][12]. Research and Development Progress - The company is advancing two TYK2 inhibitors, with CP-332 in Phase III clinical trials for AD and CP-448 in Phase III for psoriasis, both expected to complete patient enrollment in 2025 [4][12]. - Key upcoming R&D catalysts include new indication approvals and important data readouts for Oubatinib and other drugs [4][12]. Market Expectations - The current market capitalization is approximately HKD 20.066 billion, with a recent average trading volume of HKD 121 million over the past three months [5][12]. - The stock price has ranged between HKD 4.2 and HKD 11.0 over the past 52 weeks, with the current price at HKD 9.5, indicating a potential upside of 23% to the target price [5][12].

Group 1 - The core issue revolves around the investigation of the controlling shareholder, Jiang Wei, for insider trading, which has raised concerns about potential related party transactions and market trust in the company [1][2] - The company reported a significant decline in revenue growth, with a 1.64% increase projected for 2024, marking a four-year low, while traditional business segments are experiencing revenue declines [2][3] - The company's reliance on acquisitions for growth is being questioned, as the integration of acquired entities has shown mixed results, and R&D investment has decreased significantly [3][4] Group 2 - The company faces internal challenges, including governance issues and declining performance, while external pressures from industry competition and pricing strategies are intensifying [4] - The medical aesthetics sector is becoming increasingly competitive, with other players also facing challenges, indicating a potential end to the high-growth phase for hyaluronic acid products [3][4] - To regain market confidence, the company must address compliance, innovate in R&D, and diversify its business operations [4]

Core Viewpoint - The ETF market shows mixed performance, with the S&P Oil & Gas ETF leading gains while the ChiNext 50 ETF experiences significant losses [1] Group 1: ETF Performance - The S&P Oil & Gas ETF (159518) increased by 3.22% [1] - The Chemical Industry ETF (516570) rose by 3.21% [1] - The S&P Oil & Gas ETF (513350) gained 3.19% [1] - The ChiNext 50 ETF (588720) declined by 3.83% [1] - The S&P Biotechnology ETF (159502) fell by 1.65% [1] - The Photovoltaic ETF Index Fund (159618) decreased by 1.45% [1]

Core Viewpoint - Shanghai Univi Technology Co., Ltd. plans to repurchase part of its A-shares using its own funds, with a total amount between RMB 15 million and RMB 30 million, to be used for cancellation and reduction of registered capital [2][5]. Group 1: Repurchase Plan Details - The repurchase will be conducted through centralized bidding, with a maximum price of RMB 44 per share [2][6]. - The implementation period for the repurchase is set to be within 12 months from the approval date by the shareholders' meeting [2][10]. - The repurchase plan has been approved by the board of directors and the shareholders' meeting held on April 10 and May 13, 2025, respectively [2][5][16]. Group 2: Shareholder Reduction Plans - Major shareholders, including Shanghai Chuangye Jieli Taili Venture Capital Center, plan to reduce their holdings by up to 2,572,172 shares, not exceeding 3% of the total share capital after excluding repurchased shares [3][13]. - As of the report date, the reduction plan has not yet commenced [3][13]. Group 3: Financial Implications - The total amount for the repurchase is estimated to allow for the acquisition of approximately 340,909 to 681,818 shares, representing 0.39% to 0.79% of the current total share capital [8][11]. - The repurchase will be funded entirely by the company's own funds, ensuring that it does not adversely affect the company's debt repayment ability or ongoing operations [10][12]. Group 4: Compliance and Procedures - The company has opened a dedicated securities account for the repurchase, which will only be used for this purpose [3][17]. - The company will notify creditors regarding the repurchase and provide them with the opportunity to claim debts or request guarantees within 45 days of notification [21][22].